resource source identifier antibodies rabbit anti cul4a bethyl laboratories cat  (Bethyl)

Journal: Oncology Reports

Article Title: KDM5D expression is lost in cisplatin-resistant neuroblastoma cells

doi: 10.3892/or.2026.9084

Figure Lengend Snippet: KDM5D and CDDP treatment affect expression of CUL4A in UKF-NB-3 and UKF-NB-3 CDDP. Flow cytometry analysis in (A) UKF-NB-3 and UKF-NB-3 CDDP , where sensitive cell line UKF-NB-3 showed lower expression of CUL4A gene compared with the resistant cell line (P<0.05) and this expression increased in sensitive cells after CDDP treatment (P<0.001) compared with control. (B) Silencing of KDM5D increased of CUL4A level (P<0.001). (C) In the CDDP-resistant cell line UKF-NB-3 CDDP , KDM5D overexpression decreased CUL4A expression compared with mock and control plasmid (P<0.001). CDDP treatment of overexpressed cells with KDM5D increased the level of CUL4A (P<0.001), while in control cells CDDP treatment did not change the level of CUL4A. Data are shown as mean ± standard deviation from three independent experiments. Statistical significance was determined using two-way ANOVA with Tukey's post hoc test. *P<0.05; **P<0.01; ***P<0.001 (ANOVA with Tukey's post hoc test). CTR, control; NC, non-coding RNA; si, short interfering RNA; pl, ORF-clone plasmid; NB3, UKF-NB-3; Mock/NC, control cells; siKDM5D/pl-KDM5D, control cells transfected with siKDM5D/pl-KDM5D; FC, flow cytometry.

Article Snippet: After washing, the cell pellets were blocked with 5% BSA in PBS for 1 hour at room temperature After blocking, the pellets were incubated with the primary antibody anti-JARID1D rabbit mAB at a dilution of 1:100 (cat. no. PA5-100844; Invitrogen, Thermo Fisher Scientific, Inc.), anti-JARID1B rabbit mAB at dilution of 1:400 (cat. no. 15327S; Cell Signaling Technology, Inc.), anti-trimethyl histone H3 (Lys4) rabbit (cat. no. 07-473; MilliporeSigma) at a dilution of 1:400, Cleaved-Caspase 3 (Asp175) Rabbit mAB at a dilution of 1:50 (cat. no. 9602S; Cell Signaling Technology, Inc.) or CUL4A Rabbit mAB at a dilution of 1:50 (cat. no 2699; Cell Signaling Technology, Inc.) for 1 h at laboratory temperature.

Techniques: Expressing, Flow Cytometry, Control, Over Expression, Plasmid Preparation, Standard Deviation, Small Interfering RNA, Transfection

Journal: Oncology Reports

Article Title: KDM5D expression is lost in cisplatin-resistant neuroblastoma cells

doi: 10.3892/or.2026.9084

Figure Lengend Snippet: Kaplan-Meier curves analyzing KDM5D (A, B, C) and CUL4A (D, E, F) expression data and overall survival of patients in the SEQC neuroblastoma dataset (498; RPM; seqcnb1): (A) Male patients with stages 1, 2, 3 and 4S, KDM5AD expression. (B) Male patients with stage 4, KDM5D expression. (C) All male patients according to the International Neuroblastoma Staging System, KDM5D expression. (D) Male patients with stages 1, 2, 3 and 4S, CUL4A expression. (E) Male patients with stage 4, CUL4A expression. (F) All male patients according to the International Neuroblastoma Staging System, CUL4A expression. Statistical significance of survival differences was determined using the log-rank (Mantel-Cox) test. R2: Genomics Analysis and Visualization Platform revealed that low relative expression of KDM5D and high expression of CUL4A is associated with worse survival.

Article Snippet: After washing, the cell pellets were blocked with 5% BSA in PBS for 1 hour at room temperature After blocking, the pellets were incubated with the primary antibody anti-JARID1D rabbit mAB at a dilution of 1:100 (cat. no. PA5-100844; Invitrogen, Thermo Fisher Scientific, Inc.), anti-JARID1B rabbit mAB at dilution of 1:400 (cat. no. 15327S; Cell Signaling Technology, Inc.), anti-trimethyl histone H3 (Lys4) rabbit (cat. no. 07-473; MilliporeSigma) at a dilution of 1:400, Cleaved-Caspase 3 (Asp175) Rabbit mAB at a dilution of 1:50 (cat. no. 9602S; Cell Signaling Technology, Inc.) or CUL4A Rabbit mAB at a dilution of 1:50 (cat. no 2699; Cell Signaling Technology, Inc.) for 1 h at laboratory temperature.

Techniques: Expressing

Journal: Oncology Reports

Article Title: KDM5D expression is lost in cisplatin-resistant neuroblastoma cells

doi: 10.3892/or.2026.9084

Figure Lengend Snippet: KDM5D and CDDP treatment affect expression of CUL4A in UKF-NB-3 and UKF-NB-3 CDDP. Flow cytometry analysis in (A) UKF-NB-3 and UKF-NB-3 CDDP , where sensitive cell line UKF-NB-3 showed lower expression of CUL4A gene compared with the resistant cell line (P<0.05) and this expression increased in sensitive cells after CDDP treatment (P<0.001) compared with control. (B) Silencing of KDM5D increased of CUL4A level (P<0.001). (C) In the CDDP-resistant cell line UKF-NB-3 CDDP , KDM5D overexpression decreased CUL4A expression compared with mock and control plasmid (P<0.001). CDDP treatment of overexpressed cells with KDM5D increased the level of CUL4A (P<0.001), while in control cells CDDP treatment did not change the level of CUL4A. Data are shown as mean ± standard deviation from three independent experiments. Statistical significance was determined using two-way ANOVA with Tukey's post hoc test. *P<0.05; **P<0.01; ***P<0.001 (ANOVA with Tukey's post hoc test). CTR, control; NC, non-coding RNA; si, short interfering RNA; pl, ORF-clone plasmid; NB3, UKF-NB-3; Mock/NC, control cells; siKDM5D/pl-KDM5D, control cells transfected with siKDM5D/pl-KDM5D; FC, flow cytometry.

Article Snippet: The following primary antibodies were used: KDM5D Rabbit pAb (cat. no. PA5-100844; Thermo Fisher Scientific, Inc.), was diluted to a concentration of 1:500, while CUL4A Rabbit pAb (cat. no. 2699S; Cell Signaling Technology Inc.) was diluted to 1:1,000.

Techniques: Expressing, Flow Cytometry, Control, Over Expression, Plasmid Preparation, Standard Deviation, Small Interfering RNA, Transfection

Journal: Oncology Reports

Article Title: KDM5D expression is lost in cisplatin-resistant neuroblastoma cells

doi: 10.3892/or.2026.9084

Figure Lengend Snippet: Kaplan-Meier curves analyzing KDM5D (A, B, C) and CUL4A (D, E, F) expression data and overall survival of patients in the SEQC neuroblastoma dataset (498; RPM; seqcnb1): (A) Male patients with stages 1, 2, 3 and 4S, KDM5AD expression. (B) Male patients with stage 4, KDM5D expression. (C) All male patients according to the International Neuroblastoma Staging System, KDM5D expression. (D) Male patients with stages 1, 2, 3 and 4S, CUL4A expression. (E) Male patients with stage 4, CUL4A expression. (F) All male patients according to the International Neuroblastoma Staging System, CUL4A expression. Statistical significance of survival differences was determined using the log-rank (Mantel-Cox) test. R2: Genomics Analysis and Visualization Platform revealed that low relative expression of KDM5D and high expression of CUL4A is associated with worse survival.

Article Snippet: The following primary antibodies were used: KDM5D Rabbit pAb (cat. no. PA5-100844; Thermo Fisher Scientific, Inc.), was diluted to a concentration of 1:500, while CUL4A Rabbit pAb (cat. no. 2699S; Cell Signaling Technology Inc.) was diluted to 1:1,000.

Techniques: Expressing